EVALUATION OF BIOLOGIC THERAPY VERSUS TRIPLE DMARD THERAPY IN RA PATIENTS UNRESPONSIVE TO METHOTREXATE

被引：0
|
作者：
Vernice, Nicholas A. [1 ]
Reiss, Allison B. [1 ]
Renna, Heather A. [1 ]
DeLeon, Joshua [1 ]
Carsons, Steven [1 ]
Kasselman, Lora J. [1 ]
机构：
[1] NYU Winthrop Hosp, Biomed Res, Mineola, NY USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2018年 / 66卷 / 03期
关键词：
D O I：
10.1136/jim-2018-000730.2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2
引用
收藏
页码：697 / 697
页数：1
相关论文
共 50 条
  • [41] Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept
    Peper, Shana M.
    Lew, Robert
    Mikuls, Ted
    Brophy, Mary
    Rybin, Denis
    Wu, Hongseng
    O'Dell, James
    ARTHRITIS CARE & RESEARCH, 2017, 69 (10) : 1467 - 1472
  • [42] Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naive RA patients? A systematic review
    Sahbudin, Ilfita
    Singh, Ruchir
    Trickey, Jeanette
    Baranskaya, Aliaksandra
    Tracy, Alexander
    Raza, Karim
    Filer, Andrew
    Jowett, Sue
    Boonen, Annelies
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2023, 7 (02)
  • [43] Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis
    Curtis, Jeffrey R.
    Palmer, J. Lynn
    Reed, George W.
    Greenberg, Jeffrey
    Pappas, Dimitrios A.
    Harrold, Leslie R.
    Kremer, Joel M.
    ARTHRITIS CARE & RESEARCH, 2021, 73 (08) : 1114 - 1124
  • [44] Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure
    SiNi Li
    JianHe Li
    LiuBao Peng
    YaMin Li
    XiaoMin Wan
    Rheumatology and Therapy, 2021, 8 : 775 - 791
  • [45] Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 775 - 791
  • [46] ADHERENCE AND PERSISTENCE WITH TRIPLE NON-BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG THERAPY AND ETANERCEPT-METHOTREXATE COMBINATION THERAPY IN US PATIENTS WITH RHEUMATOID ARTHRITIS
    Bonafede, M.
    Johnson, B. H.
    Tang, D.
    Shah, N.
    Harrison, D.
    Collier, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 335 - 335
  • [47] Triple therapy with non-biologic DMARDs for rheumatoid arthritis or biologic therapy. Is it the same?
    Abud-Mendoza, Carlos
    Martinez-Martinez, Marco U.
    REUMATOLOGIA CLINICA, 2014, 10 (05): : 345 - 346
  • [48] Adverse effects of low-dose glucocorticoids and DMARD therapy in patients with RA—a complex relationship?
    John Kirwan
    Nature Clinical Practice Rheumatology, 2008, 4 : 568 - 569
  • [49] HEALTH CARE COSTS IN PSORIASIS PATIENTS NEWLY INITIATED ON A BIOLOGIC THERAPY OR METHOTREXATE
    Zhang, F.
    Hiscock, R.
    VALUE IN HEALTH, 2014, 17 (03) : A285 - A285
  • [50] The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy
    Erhardt, Daniel
    Sauer, Brian C.
    Teng, Chia-Chen
    Mikuls, Ted R.
    Curtis, Jeffrey R.
    Cannon, Grant W.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345